Cambrian Biopharma's James Peyer: "70 will be the new 50"

The Sunday Times’ tech correspondent brings on James Peyer, co-founder of Cambrian Biopharma, to talk about the unique structure of his startup (6:30), the goal (8:45), alighting on longevity as a 15-year-old (12:45), why the field has matured (15:40), what he chooses to focus on (19:50), getting drugs to market (24:55), raising money (32:00), why he chose the name (38:30), why dying of old age not necessarily an evolutionary inevitability (41:00), and the vaccine model (45:00), 

See acast.com/privacy for privacy and opt-out information.